Back to: Psychedelics, Entheogens, and Consciousness Expansion
Bridging the Gap:
Scientific Evidence vs. Institutional Readiness in Psychedelic Medicine
In the summer of 2024, MDMA assisted therapy for PTSD had trial numbers most of psychiatry would be thrilled to report, and the FDA turned it down anyway. Less than two years later, in the spring of 2026, a president signed an executive order to speed the whole field along, and the FDA began handing out vouchers that shrink a year long review into a matter of weeks. Read those two facts back to back and the field looks either broken or vindicated, depending on which one you read last. Neither reading is right. What happened is that two different clocks were running the entire time, at two different speeds, and most of us were only watching one of them.
This companion piece is about learning to watch both. It is not a footnote to Module 1 so much as a magnifying glass held over one of its most important ideas: that scientific progress and institutional approval are not the same event, and confusing them is how good stories turn into bad conclusions.
The Evidence Clock and the Readiness Clock
Call the first one the evidence clock. It runs on clinical data: response rates, placebo comparisons, the slow accumulation of trials that either replicate or fail to. It moves at the speed of biology and careful measurement, which is to say, slowly, and mostly indifferent to headlines.
Call the second one the readiness clock. It runs on something else entirely: regulatory precedent, institutional comfort, political will, and the procedural mechanics of an agency that has to answer for every approval it grants. It can sit still for years and then lurch forward in a single spring. It is not measuring whether a treatment works. It is measuring whether the system trusts the evidence enough, and trusts itself enough, to say so publicly.
Most of the confusion in this field, and I would argue in how the public reads medical news generally, comes from assuming these two clocks tell the same time. They do not. A compound can have remarkable data and still wait years for approval, because the readiness clock has not caught up. A compound can also move through approval faster than its scientific novelty would predict, because the readiness clock was already comfortable with its chemical neighborhood. Neither outcome is a verdict on the medicine itself.
Two Ways to Misread the Same Field
Watching this unfold since 2024, I have noticed readers tend to fall into one of two traps, and they are mirror images of each other.
The first is reactive pessimism: treating a regulatory rejection, such as the 2024 MDMA decision, as proof that the entire field was cynically overhyped from the start. The second is premature finality: treating a burst of administrative acceleration, such as the 2026 priority vouchers, as proof that the underlying science is now fully settled. Both errors share the same root. They collapse two clocks into one and then read whichever clock is currently in motion as the whole truth.
I would rather you leave this piece slightly less certain and considerably more accurate than the alternative. That is the trade this whole course keeps asking you to make.
What Extraordinary Data Could Not Buy
The MDMA story is the clearest illustration we have of the evidence clock running well ahead of the readiness clock, and it is worth sitting with in some detail.
Six Phase 2 trials sponsored by MAPS, conducted between 2004 and 2017, found that fifty four percent of participants who received full dose MDMA assisted therapy no longer met diagnostic criteria for PTSD after two sessions, compared with twenty three percent in the placebo therapy control group. The FDA was sufficiently impressed to grant Breakthrough Therapy Designation in 2017. The Phase 3 trials that followed, run by MAPS’s public benefit corporation, later renamed Lykos Therapeutics, reported that sixty-seven to seventy one percent of participants no longer met PTSD criteria at the end of treatment. By the ordinary standards of psychiatric research, those numbers are close to extraordinary.
And in June 2024, an independent FDA advisory committee voted nine to two against recommending approval anyway. The Complete Response Letter that followed in August laid out why, and the reasons had almost nothing to do with whether MDMA relieved PTSD symptoms and everything to do with whether the trial itself could be trusted. Roughly forty percent of participants had prior experience with MDMA, which made it functionally difficult to keep the trial genuinely blinded. There were unreported adverse events, including euphoric responses that the agency considered relevant to assessing abuse potential and that should have been documented. There was at least one documented case of therapist misconduct during a Phase 2 session. And the data simply did not answer how long the benefits lasted, or what retreatment should look like, because the long term follow up design had real gaps.
The fallout was immediate and severe. The journal Psychopharmacology retracted three MAPS linked studies over undisclosed conflicts of interest tied to the same misconduct allegation. Lykos cut roughly three quarters of its staff. None of that erased the Phase 2 and Phase 3 numbers. It simply confirmed, in the most concrete way possible, that a therapy can work and still not be ready, in the institution’s eyes, to be trusted at scale.
The lesson here is not that the FDA got it wrong, and it is not that MDMA does not work. It is that these are two separate questions, and the second one has its own evidentiary standard that no amount of efficacy alone can satisfy.
Why Some Drugs Get a Shorter Road
Institutional comfort matters as much as scientific novelty, sometimes more, and Esketamine is the cleanest example we have.
Esketamine, sold under the brand name Spravato, was approved in 2019 for treatment resistant depression. It is pharmacologically distinct from the classic psychedelics, an NMDA receptor antagonist rather than a serotonin 5-HT2A agonist, and its dissociative effects are experientially quite different from the visionary, often unitive states associated with psilocybin or LSD. Its comparatively fast path through the FDA had less to do with superior safety or efficacy data than with the plain fact that medicine already had decades of institutional familiarity with dissociative anesthetics.
Classic psychedelics do not get that head start. Psilocybin and LSD are asking an institution to extend trust to a class of drugs it has spent half a century treating as dangerous and without medical value. That history does not show up anywhere in a clinical trial’s statistics, and it still shapes how long the readiness clock takes to catch up.
The Readiness Clock Jumps Ahead
By early 2026, the readiness clock had started moving fast, even though the evidence clock had not changed its pace at all.
On April 18, 2026, President Trump signed an executive order directing federal agencies to accelerate research, review, and approval of psychedelic drugs for serious mental health conditions that have not responded to standard treatment. Six days later, on April 24, the FDA issued National Priority Vouchers, a mechanism that compresses the standard ten to twelve month drug application review down to roughly one to two months, to three companies: Compass Pathways, for its synthetic psilocybin formulation COMP360, targeting treatment resistant depression; the Usona Institute, for psilocybin aimed at major depressive disorder more broadly; and Transcend Therapeutics, for methylone, an MDMA related but chemically distinct compound, targeting PTSD.
Compass Pathways is the furthest along, and its data is genuinely notable. The company reported the first positive Phase 3 result for any classic psychedelic in United States history, with COMP005 topline results in June 2025 and COMP006 topline results in February 2026. In the COMP006 trial, thirty nine percent of participants in the twenty five milligram arm achieved a clinically meaningful reduction in depression severity by week six. Follow up data released in July 2026 showed the benefit holding through six months, with roughly a third of responders reaching full remission by week twenty six. Compass has already submitted its New Drug Application, with a decision possible by late 2026 or early 2027.
It would be easy to read all of this as vindication and stop there, and that would be exactly the premature finality this piece has been warning against. The executive order does not, by itself, approve any drug or lower the FDA’s evidentiary bar. FDA Commissioner Marty Makary has been explicit on this point, stating publicly that the agency’s development standards must stay grounded in sound science and rigorous clinical evidence, and that any approved therapy would be delivered only in a controlled, supervised setting, in a hospital, not as a take home prescription. In his words, these are not medications anyone will simply pick up at a pharmacy.
A Trial Built to Listen
Transcend Therapeutics’ methylone program deserves particular attention, because it was not built to resubmit the same MDMA story and hope for a different outcome. It was built, deliberately, to answer the FDA’s stated objections to the Lykos trials. Methylone is chemically distinct from MDMA, which addresses part of the blinding concern, and the trial protocols were modified with the Complete Response Letter’s specific criticisms in mind: tighter control over prior drug experience among participants, more rigorous adverse event reporting, and a clearer plan for assessing durability over time.
Whether that redesign succeeds is still an open question. But the attempt itself is instructive. It shows a sponsor treating a regulatory rejection not as a verdict on the science but as a detailed list of what the readiness clock still needed to see. That is, in miniature, exactly the kind of response this course keeps asking of you as a reader: take the setback seriously as information, not as a final word.
What Has Not Changed
Strip away the executive order, the vouchers, and the compressed timelines, and one fact remains exactly where it was in 2024: the FDA still requires substantial evidence of safety and efficacy before it will approve anything. Procedural speed is not the same as a lowered bar. What changed in the spring of 2026 was momentum, political and administrative. What did not change was the underlying scientific standard a compound has to clear.
That distinction is the whole point of this companion piece, and it is worth carrying with you well beyond this course. A reader who took the 2024 MDMA rejection as proof the field was cynically overhyped would have been wrong within two years. A reader who takes the 2026 vouchers as proof the science is now fully settled is making the same mistake, just pointed in the other direction.
Reading the Two Clocks
The psychedelic renaissance, if that word still fits by the time you read this, was never going to move in a straight line. It includes real setbacks that function as essential data for the next round of trial design, and it includes real acceleration that has not, on its own, resolved a single open scientific question. Both things are true at once and holding them at once is the actual discipline this field is asking of you.
So, the next time a headline tells you a treatment has failed or succeeded, do yourself a favor before you believe it either way. Ask which clock the headline is reporting on. Ask whether the claim is about biology, the trial’s integrity, or the institution’s comfort with releasing it into the world. Those are three different questions, and the gap between them is exactly where this entire field currently lives.